The report "Global Plasma Fractionation Market, By Product Type (Albumin, Immunoglobulins, Coagulation factor concentrates, and Others), By Application (Neurology, Hematology, Immunology, Critical Care, and Others), By End User (Hospitals and Clinics, Clinical Research Laboratories, and Academic Institutes), and Region - Global Forecast to 2030"
Plasma Fractionation Market accounted for US$ 25.6 billion 2020 and is estimated to be US$ 52.64 billion by 2030 and is anticipated to register a CAGR of 7.5%. Rising incidence of immunologic disorders and growing use of immunoglobulin and alpha-1 antitrypsin are major factors driving growth of the global plasma fractionation market. In addition, increasing awareness of diseases such as hemophilia and rising incidence of sudden spreading of viral diseases across the globe are some among the major factors to raise the stakes for plasma fractionation by diagnostic centers. This factor leads to large-scale protein purification and ultimately propelling growth of the global plasma fractionation market. Innovation and development in cost effective plasmapheresis equipment’s by manufacturers and increasing number of hemophilic patients can create lucrative opportunity for players operating in the global plasma fractionation market.
Key Highlights:
· In December 2017, BioLife Plasma Services L. P. had files for FDA approval of a new plasma manufacturing facility in Covington, Georgia to support growing immunology franchise.
Key Market Insights from the report:
The Global Plasma Fractionation Market accounted for US$ 25.6 billion 2020 and is estimated to be US$ 52.64 billion by 2030 and is anticipated to register a CAGR of 7.5%. The market report has been segmented on the basis of product type, application, end user, and region.
· By product type, the immunoglobulins segment is accounted for major revenue share in 2018, since it reduces adverse effects and drug reactions.
· By application, the neurology segment is accounted for major revenue share in 2018, owing to rising incidences of neurological disorders and increasing aging population.
· By end-user, the hospitals and clinics segment is accounted for major revenue share in 2018. This is due to improving infrastructure and healthcare facilities provided by hospitals, along with increasing off-label (non-approved) use of plasma fractionated products in hospitals for excessive bleeding due to trauma and surgery.
· By region, North America plasma fractionation market accounted for major revenue share of the global plasma fractionation market and is further anticipated to maintain its dominance over the forecast period. Due to increasing use of immunoglobulins in neurological diseases, and availability of appropriate healthcare infrastructure in the countries of the North America region. Europe plasma fractionation market accounted for second-highest market share, in 2018. This is due to increasing use of plasma fractioned in neurological diseases, in treatment hemophilic patients, and increasing use of prophylaxis treatments for diagnosed patients in this region. Asia Pacific plasma fractionation market is expected to grow at the highest rate during the forecast period owing to high expenditure for development of proper healthcare infrastructure by governments of countries in the region
Before purchasing this report, request a sample or make an inquiry by clicking the following link:
https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/537
.
The prominent player operating in the global plasma fractionation market includes CSL Plasma, Inc., Grifols S.A., BioLife Plasma Services L. P., Octapharma Plasma, Inc., Kedrion S.p.A, Bio Product Laboratory Ltd., LFB S.A., Biotest Pharmaceuticals Corporation, Japan Blood Products Organization, and China Biologic Products Holdings, Inc.
